Company Overview

Vijaya Diagnostic Centre Limited (CIN: L85195TG2002PLC039075) reported strong financial and operational performance for FY2025-26, demonstrating robust growth across key metrics while maintaining regulatory compliance and executing strategic initiatives.

Financial Performance Highlights

Revenue: ₹814.20 crore (19.5% growth YoY from ₹681.39 crore in FY25)

EBITDA: ₹336.9 crore (23.3% growth YoY) with margin of 41.4%

Profit After Tax: ₹173.0 crore (20.3% growth from ₹143.79 crore)

Basic EPS: ₹16.81 (₹17.33 standalone)

Diluted EPS: ₹16.79 (₹17.31 standalone)

Other Income: ₹207.99 crore including interest income (₹56.34 crore), gain on sale of mutual funds (₹72.95 crore), and fair value gains (₹45.14 crore)

Expenses: Employee benefits (₹130.74 crore), depreciation (₹91.82 crore), finance costs (₹33.23 crore), and other expenses (₹251.84 crore)

Tax Expense: ₹59.70 crore (effective rate 25.66%)

Operational Metrics & Expansion

Network: 162 centers across 6 states (Andhra Pradesh, Telangana, West Bengal, Maharashtra, Karnataka, NCR)

FY26 Expansion: 10 new hub centers added

Tests Conducted: 16.92 million

Patient Footfalls: 4.68 million

Revenue per Footfall: ₹1,740

B2C Revenue Contribution: 92%

Workforce: 3,000+ employees

Significant Corporate Actions

Medinova Amalgamation: Completed amalgamation with Medinova Diagnostic Services Limited effective April 1, 2024, approved by NCLT on October 13, 2025. Issued 171,792 equity shares to non-controlling shareholders.

Dividend: Board recommended final dividend of ₹2 per equity share (200% on face value of ₹1) for FY2025-26, subject to shareholder approval at AGM.

ESOP Expansion: Approval sought to increase Employee Stock Option Pool from 1,625,000 to 3,625,000 options. Granted 308,650 options in FY2026 with share-based payment expense of ₹1.73 crore.

Capital Structure & Shareholding

Share Capital: ₹10,28,96,728 as of March 31, 2026 (10,289.67 lakh shares)

Major Shareholders (>5%): Dr. S. Surendranath Reddy (32.23%), S. Suprita Reddy (8.72%), K. Sunil Chandra (7.56%), Kotak Small Cap Fund (6.99%), Nippon Life India Trustee (6.92%)

Subsidiaries: P H Diagnostic Centre Private Limited (wholly owned), VDC Diagnostics (Karnataka) LLP, Medinova Millennium MRI Services LLP

Balance Sheet Position

Total Assets: ₹62,069.13 lakh

Property, Plant & Equipment: ₹27,416.92 lakh

Right-of-use Assets: ₹38,754.59 lakh

Investments: ₹22,842.00 lakh (mutual funds and equity instruments)

Cash & Equivalents: ₹3,967.52 lakh

Total Equity: ₹95,715.18 lakh

Lease Liabilities: ₹42,258.50 lakh

Trade Payables: ₹3,756.30 lakh (including MSME dues of ₹279.71 lakh)

Regulatory & Compliance Matters

AGM Details: Scheduled for September 24, 2026 to approve financial statements, dividend, director reappointment (Mrs. Sura Geeta Reddy), and ESOP amendments.

Auditors: M/s. B S R and Co. (statutory), M/s. Santhosh & Associates (cost), M/s. Balaramakrishna & Associates (secretarial)

Key Audit Matters: Revenue recognition (high volume cash transactions) and impairment assessment of investments (₹142.6 crore requiring management judgment)

Contingent Liabilities: ₹14.85 lakh (service tax and GST claims)

Regulatory: Received information request from Directorate of Enforcement under FEMA; provided information with no material impact

Technology & CSR Initiatives

AI Implementation: Deployed AI-powered solutions in urology (CT KUB) and dental imaging with planned automated laboratory in Panjagutta, Hyderabad

CSR Expenditure: ₹30.96 lakh focused on skill development and healthcare initiatives including National Apprenticeship Promotion Scheme

Forward Outlook

FY27 Expansion: 8-9 hub centers and 10-12 spoke centers planned with focus on Pune, West Bengal, and accelerated Bengaluru expansion

Technology Focus: Continued investments in AI, genomics, and advanced diagnostic capabilities

All statutory compliances maintained with SEBI, MCA, and other regulatory authorities with no material penalties or non-compliances reported during the financial year.